<DOC>
	<DOC>NCT02933333</DOC>
	<brief_summary>The purpose of this study is to explore the effect of G-CSF combination with GM-CSF on prevention and treatment of infection in children with malignant tumor.</brief_summary>
	<brief_title>G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor</brief_title>
	<detailed_description>G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Hepatoblastoma</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients with malignant tumor including acute myeloid leukemia (AML) after complete remission, acute lymphocytic leukemia (ALL) after complete remission, stage III or IV lymphoma after partial remission or complete remission, stage III or IV neuroblastoma (NB) or retinoblastoma (RB). Eastern Cooperative Oncology Group performance status â‰¤ 2. Did not receive treatment of CSFs in two weeks. Without symptomatic infection and with normal values of Creactive protein or procalcitonin. The first time of ANC &lt; 1.5*10^9/L after chemotherapy. More than 24 h after the last chemotherapy. The function of liver was normal. Allergic to GMCSF or drugs which expressed in Escherichia coli. Patients with infection, diabetes or primary immunodeficiency. Patients infected with hepatitis B, hepatitis C or HIV. Patients confirmed autoimmune thrombocytopenic purpura.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>